Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its news flow reflects this specialized focus. Company announcements frequently highlight developments related to its three commercial-stage products—EXPAREL, ZILRETTA and iovera°—as well as its gene therapy candidate PCRX-201 for osteoarthritis of the knee.
On this page, readers can follow Pacira news such as commercial partnerships, clinical data, manufacturing updates and shareholder-related events. Recent releases include an agreement granting LG Chem exclusive rights to commercialize EXPAREL in select Asia-Pacific markets, preliminary revenue updates emphasizing EXPAREL sales, and data from a pilot study showing favorable safety and pain reduction with iovera° compared with radiofrequency ablation in chronic low back pain.
Pacira also issues news about its participation in scientific and investor conferences, including presentations at major healthcare conferences, and its involvement in collaborative research efforts. For example, the company announced that it joined the PROBE Consortium, a public‑private initiative using big data and AI to improve osteoarthritis research and care, and that it will contribute data from its ASCEND study of PCRX-201.
In addition, Pacira’s news includes corporate and financial updates such as preliminary unaudited revenue results, share repurchase activity, inducement equity grants under its inducement plan, and operational changes like workforce reductions linked to manufacturing efficiency improvements. External parties such as DOMA Perpetual Capital Management LLC have also issued public letters and proxy-related communications concerning Pacira’s governance and strategic options.
Investors, analysts and healthcare professionals can use this news feed to monitor product performance, pipeline progress, strategic partnerships, financing developments and shareholder actions that may influence the outlook for PCRX stock and Pacira’s role in non-opioid pain management.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales for October 2021, noting that EXPAREL achieved sales of $42.5 million, a 4.4% increase from $40.7 million in October 2020. Average daily sales for EXPAREL rose to 109% compared to last year. Sales of iovera° were $1.2 million, up from $1.0 million in the same period. CEO Dave Stack expressed confidence in strong growth ahead, citing improved market conditions for elective surgeries. The company also plans to integrate ZILRETTA post-acquisition of Flexion Therapeutics, aiming for annual growth in the high teens and over 50% operating margins.
Pacira BioSciences (Nasdaq: PCRX) has filed a lawsuit against eVenus Pharmaceutical Laboratories for patent infringement related to EXPAREL (bupivacaine liposome injectable suspension), protecting U.S. Patent Number 11,033,495, which expires on January 22, 2041. The lawsuit triggers a 30-month stay on eVenus’ ANDA approval under the Hatch Waxman Act. This marks a significant step in Pacira's patent strategy, as the company aims to defend its intellectual property against potential generic competition.
Pacira BioSciences (Nasdaq: PCRX) reported third quarter 2021 financial results, achieving total revenues of $127.7 million, compared to $117.5 million in Q3 2020. The company recorded a GAAP net income of $17.7 million ($0.40 per share) and adjusted EBITDA of $48.1 million, up from $34.2 million a year prior. The positive trajectory is bolstered by strong EXPAREL sales, reaching $121.9 million. A proposed acquisition of Flexion Therapeutics aims to enhance growth efforts. Pacira's financial outlook remains bullish while navigating ongoing challenges from the COVID-19 pandemic.
Pacira BioSciences (Nasdaq: PCRX) has received Notice of Allowance from the USPTO for a U.S. Patent Application related to the chemical composition of EXPAREL (bupivacaine liposome injectable suspension) and a novel manufacturing process. Upon issuance, these patents will be eligible for listing in the FDA Orange Book, extending patent protection until January 22, 2041. This move enhances the company's intellectual property strategy, securing barriers against competition. CEO Dave Stack emphasized confidence in EXPAREL's market leadership across various medical procedures.
Pacira BioSciences, Inc. (NASDAQ:PCRX) is set to release its third quarter financial results on November 3, 2021, before U.S. market opening. A conference call is scheduled for 8:30 a.m. ET to discuss the results. Participants can join the call by dialing the provided numbers or accessing the webcast via the Pacira investor website. Notably, Pacira emphasizes its leadership in non-opioid pain management, particularly with its long-acting analgesic EXPAREL® and the iovera°® cryoanalgesia system, highlighting its commitment to improving patient outcomes.
Pacira BioSciences (Nasdaq: PCRX) has announced its acquisition of Flexion Therapeutics for $8.50 per share in cash, plus a contingent value right (CVR) worth up to $8.00 per share, subject to certain milestones. This acquisition adds ZILRETTA, a non-opioid therapy for osteoarthritis knee pain, to Pacira's portfolio, enhancing its commitment to non-opioid pain management. The deal is expected to be accretive to earnings in 2022 and provides significant synergies. Pacira plans to fund the transaction from existing cash resources and expects it to close in Q4 2021, pending regulatory approvals.
TAMPA, Fla., Oct. 08, 2021 – Pacira BioSciences (NASDAQ: PCRX) announces an Investor Day on October 15, 2021, from 8:00 AM to 12:00 PM ET, at its Innovation and Training Center in Tampa. Key Opinion Leaders and the executive team will discuss updates on the company's commercial products and pipeline opportunities. Attendance is limited and requires advance registration. A live webcast and archived replay will be available on PaciraInvestorDay.com.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has received a Paragraph IV Certification Notice Letter from eVenus Pharmaceutical Laboratories regarding a generic version of EXPAREL (bupivacaine liposome injectable suspension). eVenus alleges the corresponding patent is invalid. Pacira is poised to defend its patent rights and has 45 days to initiate a lawsuit. The company possesses additional patents set to extend EXPAREL's market exclusivity into the 2040s, contributing to its competitive position in non-opioid pain management.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has successfully completed process validation for its EXPAREL product, marking a key milestone in increasing its manufacturing capacity. The new 200-liter production suite in Swindon, England, developed in partnership with Thermo Fisher Scientific, is operational, with sales expected to begin by year-end 2021. This expansion aims to achieve gross margins exceeding 85 percent by 2024. Additionally, a new Orange Book-listed patent extends EXPAREL's market exclusivity to January 2041.
ImmuneID, Inc. has appointed James S. Scibetta as the new CEO, succeeding David Donabedian, who will move to an advisory role. Scibetta, with over 20 years of biotech experience, previously led Maverick Therapeutics, acquired by Takeda in April 2021, and held executive roles at Pacira Pharmaceuticals and Bioenvision. Under Donabedian's leadership, ImmuneID raised over $70 million since its launch in Q4 2020. The company focuses on precision immunology, leveraging a proprietary platform for targeting immune diseases.